Abcam, ab254575, Anti-OATP1B1 antibody

Size: 100µg
Rabbit Polyclonal OATP1B1 antibody. Suitable for ICC, WB and reacts with Human samples. Cited in 1 publication. Immunogen corresponding to Synthetic Peptide within Human SLCO1B1 aa 600 to C-terminus.
Key facts
Host species:Rabbit,
Clonality:Polyclonal,
Isotype:IgG,
Carrier free:No,
Reacts with:Human,
Applications:WB, ICCSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:Synthetic Peptide within Human SLCO1B1 aa 600 to C-terminus. The exact immunogen used to generate this antibody is proprietary information.Q9Y6L6,
Specificity:This antibody is predicted to not cross-react with other SLCO1B proteins.

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Immunogen, Storage buffer-pH: 7.2Preservative: 0.02% Sodium azideConstituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C, Storage information-Avoid freeze / thaw cycle

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
OATP1B1 also known as SLCO1B1 is a solute carrier organic anion transporter protein with a mass of approximately 85 kDa. This protein operates mechanically by transporting endogenous compounds and xenobiotics such as drugs across liver cell membranes. The primary expression of OATP1B1 occurs in the liver specifically on the basolateral membrane of hepatocytes. This localization facilitates its essential role in hepatic uptake of a variety of substances playing a critical role in pharmacokinetics.
Biological function summary
OATP1B1 contributes prominently to drug metabolism and clearance. It actively transports diverse substrates including bile acids bilirubin and drugs such as statins. While not part of a larger complex OATP1B1 functions alongside other hepatic transporters to ensure efficient clearance and detoxification processes in the liver. The activity of OATP1B1 is fundamental for maintaining drug concentrations within therapeutic ranges thereby protecting against toxicity.
Pathways
OATP1B1 is part of the hepatic drug metabolic pathway and the bile acid synthesis pathway. It works in coordination with other transporters like OATP1B3 and NTCP which also mediate hepatic uptake of organic anions and bile acids. The interaction among these transporters regulates the systemic levels of endogenous compounds and the clearance of therapeutic drugs influencing their efficacy and safety profiles.
OATP1B1 is linked to altered drug metabolism leading to statin-associated myopathy. Genetic variations in the OATP1B1 gene can reduce transporter function resulting in increased plasma concentration of statins which correlates with myopathy risk. Additionally OATP1B1 mutations may affect bilirubin handling contributing to conditions such as Rotor syndrome. Through these associations OATP1B1 interacts with other proteins affecting drug safety and disease states emphasizing its relevance in personalized medicine.